Lenalidomide-based Regimens for Multiple Myeloma - Med India

Treatment for multiple myeloma includes bone marrow transplantation, radiation and chemotherapy. Chemotherapy earlier included two medications, melphalan and prednisone. Later, other medications like thalidomide, bortezomib and lenalidomide were added to ...

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM - News-Medical.Net

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma (MM-015) This double-blind, phase III, multicenter, randomized study conducted by Celgene compared melphalan-prednisone-lenalidomide induction followed by lenalidomide ...

Celgene (CELG) Unit Reports Publication of Three REVLIMID Studies in MM Patients - StreetInsider.com

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma (MM-015) This double-blind, phase III, multicenter, randomized study conducted by Celgene compared melphalan–prednisone–lenalidomide induction followed by lenalidomide maintenance ...

Revlimid Delays Relapse in Multiple Myeloma - MedPage Today

In the first trial, researchers led by Antonio Palumbo, MD, of the University of Turin in Italy compared three regimens in 459 patients 65 or older: Induction with melphalan (Alkeran), prednisone, and lenalidomide, followed by lenalidomide ...

Iraqi cancer patient finds hope in India - Newstrack India

But the process was not easy. "Abdul was treated with a medicine, Melphalan, for a year and a half, which was damaging to stem cells. The only solution was bone marrow transplant. So using a different regime, we developed adequate stem cells and ...

Research and Markets: Amyloidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - Boston Globe

The current off-label drugs prescribed to treat AL amyloidosis, such as melphalan, cyclophosphamide, vincristine, dexamethasone, prednisolone and Thalomid (thalidomide) and doxorubicin, lack efficacy and safety. As a result, the median survival ...

Delcath Announces Proposed Public Offering Of Common Stock And Warrants - Stockhouse

The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company's website at www.delcath.com. Private ...

New England Journal of Medicine Reports on Three Phase III REVLIMID(R...  - CNBC

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma (MM-015) This double-blind, phase III, multicenter, randomized study conducted by Celgene compared melphalan--prednisone--lenalidomide induction followed by lenalidomide maintenance ...

Delcath to Webcast Management's Presentation at Annual Meeting of Stockholders - Stockhouse

The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company's website at www.delcath.com. The Private ...

Lenalidomide Maintenance Beneficial in Multiple Myeloma - Medscape News

001). Maintenance Therapy in Newly Diagnosed Patients The Italian researchers compared the efficacy and safety of melphalan/prednisone/lenalidomide (MPR) induction therapy followed by lenalidomide maintenance therapy with MPR or melphalan/prednisone (MP ...